GSK Pushing For ADOPTion Of Avandia For First-Line Type 2 Diabetes Therapy
Executive Summary
GlaxoSmithKline plans to use the results of its ADOPT study to establish its thiazolidinedioneAvandia as the standard first-line treatment for type 2 diabetes
You may also be interested in...
GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak
If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void
GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak
If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void
GSK Plays Up Avandia As Diabetes “Engine” After DPP-4 Program Stalls
GlaxoSmithKline does not believe development of its own dipeptidyl peptidase-4 inhibitor is integral to growing the firm's diabetes franchise